Company overview
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Daily valuation snapshot
These values are from the stored daily market snapshot dated 2026-10-08. They are not a live quote.
| Daily close (USD) | $5.64 |
| Market capitalization (USD) | $3,046,248.6 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.81 |
No matching rows. Clear the filter to see all records.
Continue the research
Read public ownership disclosures separately from company fundamentals. Test a strategy against dated historical observations before evaluating its assumptions; a past result is not a live trading outcome.